Issued 2026-08-13 at $84.46 · now $84.44 (2026-08-13, −0.0% since)
Based on its own history, a month from the 2026-08-13 close, CRNX has typically landed between $68.09 and $107.78 — a range of −19.4% to +27.6% from the issuance price $84.46.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
2,006 overlapping 1 month windows · 2018-07-18 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($84.46) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where CRNX has typically landed a month from the 2026-08-13 close of $84.46 — the range is history, not a prediction.
- now $84.44 (-0.0%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $84.93 (+0.6%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $77.41–$92.45
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $68.09–$107.78
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2020-02-13 | −49.0% | −49.0% | +7.0% |
| 2020-02-18 | −48.1% | −48.4% | +8.4% |
| 2020-02-20 | −45.4% | −52.4% | +0.0% |
| 3 best | |||
| 2026-06-05 | +154.0% | +0.0% | +154.0% |
| 2026-06-11 | +150.2% | +0.0% | +150.2% |
| 2026-06-08 | +149.6% | +0.0% | +149.8% |
2,006 overlapping windows · 2018-07-18 – 2026-08-13 · not cherry-picked
Pending catalysts
- October 2026 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome (source, as of 2026-08-14)
- May 2027 — Trial primary completion: Phase 3 primary completion: A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia (source, as of 2026-08-14)
- August 2027 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors (source, as of 2026-08-14)
- August 2027 — Trial primary completion: Phase 3 primary completion: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen (source, as of 2026-08-14)
- July 2029 — Trial primary completion: Phase 2 primary completion: An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia (source, as of 2026-08-14)
- March 2030 — Trial primary completion: Phase 2/Phase PHASE3 primary completion: A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~9 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.